Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2013

View Archived Issues

Bivalent norovirus vaccine protects against illness in oral challenge study

Varicella zoster vaccine candidate is immunogenic in patients with HIV infection

CD151 antigen expression correlated with progression in advanced gastric cancer

Bioengineering of a novel nanotechnology-based drug delivery system

Rational computational design of high-affinity, small-molecule-selective binding proteins

Anxiolytic activity demonstrated for RU-476

Mesoblast acquires Osiris' culture-expanded mesenchymal stem cell business

Novel photoimmunoconjugates discovered by German group

Researchers disclose new monoclonal antibodies for cancer and ocular disorders

Takeda Pharmaceutical prepares novel GL-R antagonists for diabetes

CCI Corporation patents new agents for cancer

New Aurora kinase inhibitors synthesized at Sunshine Lake Pharma

Clavis Pharma becomes Aqualis

Alcobra presents new findings on MG-01CI

Protalix BioTherapeutics reports phase I data for PRX-112

MannKind resubmits Afrezza NDA

Topline data from phase II TRUST-I trial in Crohn's disease reported

FDA releases drug safety communication for ponatinib

Otrexup injection approved by the FDA for several indications

Cellceutix plans to begin phase IIb trial of Brilacidin in 2014

Boehringer Ingelheim and Lilly submit application in Japan for empagliflozin

Acacia Pharma's phase II trial of APD-515 for xerostomia meets primary endpoint

Immatics raises funds to complete development of IMA-901 for renal cancer

Janssen files MAA with EMA for fixed-dose combination of darunavir and cobicistat

MedImmune acquires biotech company and invests in ADC Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...